Emcure Pharmaceuticals Q4 results: Net profit climbs 29% YoY to ₹243 crore; ₹3.6/share dividend recommended

In the corresponding period of the same period last year, it had clocked a profit of ₹188.96 crore, according to a regulatory filing.

Its revenue from operations jumped 16.7% YoY to ₹2,469.7 crore during the quarter under review, compared to ₹2,116.24 crore in the March quarter of the 2024-25 fiscal year (Q4 FY25).

During the quarter ended March 31, 2026, its domestic business recorded revenue of ₹977 crore, up 5.2% YoY from ₹929 crore in the same quarter of FY25. The domestic business reported a softer performance, largely due to the Zuventus portfolio and team reorganisation.

On the other hand, its international business saw robust revenue growth of 25.7% YoY, with sales at ₹1,493 crore for the reporting quarter, as against ₹1,187 crore in the January-March quarter of FY25. It saw strong growth across its international markets, as it was supported by base business ramp-up and new launches.

At an operational level, its EBITDA (earnings before interest, tax, depreciation and amortisation), also known as operating profit, stood at ₹485 crore for the March FY26 quarter, marking a 24.5% YoY increase from ₹390 crore in the year-ago period.

Its EBITDA margin expanded to 19.7% for the reporting quarter, from 18.4% in Q4 FY25.

Final dividend

The company’s board of directors also recommended a final dividend of ₹3.60 per equity share with a face value of ₹10 each, at the rate of 36%, for the financial year ended March 31, 2026.

The dividend is subject to approval of the Members of the company at the ensuing Annual General Meeting (AGM).

The dividend, once approved by the members, will be paid within the prescribed timeline under the Companies Act, 2013, the firm stated.

What the CEO & MD said

Commenting on the performance, Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, said: “In FY26, the first year of our five-year strategic plan, Emcure delivered strong financial performance with over US$1 billion in revenue and 16.6% growth.”

He further stated that the international markets demonstrated robust momentum while its domestic business recorded steady growth.

“We strategically expanded through in-licensing, Zuventus minority buyout and bolt-on acquisitions in the UK and Canada. Our R&D pipeline in complex injectables and biosimilars remains a key driver of future value. Our priorities remain clear - to deliver sustainable, above-industry growth and consistent margin expansion, while continuing to build sustainable long-term value for all stakeholders,” Mehta added.

Shares of the Pune-based pharma company were trading 5.44% lower at ₹1,695.60 apiece on the National Stock Exchange (NSE) at around 2:44 PM, following the result announcement.

Emcure Pharmaceuticals has a total market capitalisation of ₹32,761.07 crore as of May 5, 2026, according to data on the NSE.